Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.

@article{Gulhati2017BevacizumabCW,
  title={Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.},
  author={Pat Gulhati and K. Raghav and Rachna T. Shroff and Gauri R. Varadhachary and Scott Kopetz and Milind M. Javle and Wei Qiao and Huamin Wang and Jeffrey S. Morris and Robert A. Wolff and Michael J Overman},
  journal={Cancer},
  year={2017},
  volume={123 6},
  pages={1011-1017}
}
BACKGROUND Capecitabine with oxaliplatin (CAPOX) has previously demonstrated clinical activity in patients with small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (AAC). Herein, the authors conducted a phase 2 trial to evaluate the benefit of adding bevacizumab to CAPOX. METHODS In this phase 2, single-arm, single-center, open-label study, patients aged ≥18 years with untreated, advanced SBA or AAC were recruited. Patients received capecitabine at a dose of 750 mg/m2 orally twice… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 9 times. VIEW TWEETS

Similar Papers

Loading similar papers…